AVTX- Avalo Therapeutics, Inc.

Insider activity in AVTX over the last quarter tilts toward selling: insiders offloaded a net 101,317 shares worth roughly $2.0M.

Classified under Biotechnology (Health Care sector), AVTX's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Neil Garry Arthur	190.3K	-	-
Other	Boyd Taylor	95.0K	-	-
Other	Doyle Mittie	51.8K	$1.04M	-
CFO	Sullivan Christopher Ryan	39.9K	$651.7K	-
Other	Riley Jennifer	37.0K	$725.6K	-

Buys and sells only

10 filings · page 7

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jun 10, 2021	Harrell James Archie Jr	Chief Commercial Officer	Buy	7,493	$2.28	$17,084.04	+26.6%	-22.9%	-87.0%
Jun 10, 2021	Wilkins H Jeffrey	Chief Medical Officer	Buy	912	$2.28	$2,079.36	+3.5%	-22.9%	-87.0%
May 18, 2021	Armistice Capital, LLC56	Director, 10% Owner	Buy	180,000	$2.18	$392,460.00	+0.5%	+22.0%	-85.6%
Jan 8, 2021	Armistice Capital, LLC56	Director, 10% Owner	Buy	2,500,000	$2.60	$6,500,000.00	+8.3%	-	-
Dec 10, 2020	Sullivan Christopher Ryan	Interim CFO	Buy	5,095	$2.28	$11,606.41	+172.5%	-	-
Dec 10, 2020	Harrell James Archie Jr	Chief Commercial Officer	Buy	171	$2.28	$389.54	+0.6%	-	-
Dec 10, 2020	Neil Garry Arthur	Chief Scientific Officer	Buy	3,599	$2.28	$8,198.52	+4.9%	-	-
Dec 3, 2020	Armistice Capital, LLC56	Director, 10% Owner	Buy	20,000	$2.44	$48,800.00	-	-	-
Nov 25, 2020	Armistice Capital, LLC56	10% Owner	Buy	100,000	$2.37	$236,868.64	+0.3%	-	-
Sep 4, 2020	Armistice Capital, LLC56	Director, 10% Owner	Buy	100,000	$2.20	$220,000.00	+0.3%	-	-